Transient CD19 Occupancy with Tafasitamab at the Time of Anti-CD19 Chimeric Antigen Receptor T (CART19) Cell Infusion Diminishes Severity and Incidence of CRS and Improves the Therapeutic Index of CART19 Cell Therapy in Preclinical Models
- Resource Type
- Source
- Transplantation and Cellular Therapy. 29:S11-S12
- Subject
Transplantation Molecular Medicine Immunology and Allergy Cell Biology Hematology - Language
- ISSN
- 2666-6367